Home 2018-03-28T18:05:09+00:00

Who We Are

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.

Learn More

Our Technology

EyePoint has developed three products approved by the FDA for long-term, sustained-release delivery of drug. Approved products include: ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, licensed to Alimera Sciences, and RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg and VITRASERT® (ganciclovir) 4.5 mg, licensed to Bausch & Lomb. All of our approved products utilize our proprietary DurasertTM Technology platform for small molecule delivery.

Learn More

Our Pipeline

EyePoint has a number of products in development that utilize our proven DurasertTM Technology platform.

Learn More